BeOne Medicines (ONC) Net Margin (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Net Margin data on file, last reported at 15.02% in Q1 2026.

• On a quarterly basis, Net Margin rose 1491.0% year-over-year to 15.02% in Q1 2026; TTM through Mar 2026 was 8.94%, a 1833.0% increase from a year earlier, with the FY2025 full-year figure at 5.37%, up 2229.0% from the prior year.
• Net Margin for Q1 2026 stood at 15.02%, up from 4.44% in the prior quarter.
• Over the last five years, Net Margin for ONC reached as high as 27.57% in Q3 2023 and fell as low as 165.62% in Q2 2022.
• Historically, Net Margin has averaged 45.71% across 5 years, with a median of 13.47% in 2024.
• Across the five-year window, Net Margin sank 15291 bps in 2022 and jumped 17141 bps in 2023, its largest moves.
• Year by year, Net Margin stood at 117.16% in 2022, then jumped by 51 bps to 57.94% in 2023, then soared by 77 bps to 13.47% in 2024, then surged by 133 bps to 4.44% in 2025, then soared by 238 bps to 15.02% in 2026.
• Per Business Quant data, the three most recent Net Margin figures were 15.02% in Q1 2026, 4.44% in Q4 2025, and 8.84% in Q3 2025.